Regulated, adenovirus-mediated delivery of tyrosine hydroxylase suppresses growth of estrogen-induced pituitary prolactinomas

Molecular Therapy

Volumn 4, Issue 6, 2001, Pages 593-602

  Williams, Judith C ^a   Stone, Daniel ^a   Smith Arica, Joseph R ^a   Morris, Ian D ^b   Lowenstein, Pedro R ^a   Castro, Maria G ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

Adenoviral vectors; Anterior pituitary; Gene transfer therapy; Lactotroph hyperplasia; Tetracycline regulation

Indexed keywords

AMINO ACID; DOPAMINE; DOXYCYCLINE; ESTROGEN; HORMONE PRECURSOR; PROLACTIN; SULPIRIDE; TETRACYCLINE; TYROSINE 3 MONOOXYGENASE; VIRUS VECTOR;

ADENOHYPOPHYSIS; ADENOVIRUS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER INHIBITION; CELL CULTURE; CONTROLLED STUDY; DOPAMINE METABOLISM; ENZYME SYNTHESIS; GENE EXPRESSION REGULATION; GENE OVEREXPRESSION; GENE TARGETING; GENE THERAPY; HUMAN; HUMAN CELL; HYPERPROLACTINEMIA; HYPOPHYSIS CELL; HYPOPHYSIS TUMOR; MALE; MOUSE; NONHUMAN; PROLACTIN BLOOD LEVEL; PROLACTINOMA; RAT; SOMATIC CELL; TUMOR CELL LINE;

ADENOVIRIDAE; ANIMALIA;

EID: 0035668082     PISSN: 15250016     EISSN: None     Source Type: Journal    
DOI: 10.1006/mthe.2001.0499     Document Type: Article

References (54)

1. Medical treatment of prolactinomas
2. Clinical management of prolactinomas
3. A comparison of cabergoline and bromocriptine in the treatment of hyperprolactinemic amenorrhea
4. Treatment of macroprolactinoma with cabergoline: A study of 85 patients
5. Dopamine agonists and pituitary tumor shrinkage
6. A comparative review of the tolerability profiles of dopamine agonists in the treatment of hyperprolactinaemia and inhibition of lactation
7. Resistance to bromocriptine in prolactinomas
8. Decreased expression of the two D2 dopamine receptor isoforms in bromocriptine-resistant prolactinomas
9. Pathologic hyperprolactinemia
10. Trans-sphenoidal surgery for microprolactinoma: An acceptable alternative to dopamine agonists?
11. Role of radiation therapy in clinical hormonally-active pituitary adenomas
12. The role of hypothalamic hormones in the pathogenesis of pituitary adenomas
13. Epidemiology and pathogenesis of pituitary adenomas
14. Prolactin: Structure, function, and regulation of secretion
15. Dopamine: A prolactin-inhibiting hormone
16. Neuroendocrine control of prolactin secretion
17. 3H]dihydroergocryptine binding with the dopaminergic control of prolactin release
18. Dopamine receptors on intact anterior pituitary cells in culture: Functional association with the inhibition of prolactin and thyrotropin
19. 2 receptor-regulated expression of the prolactin gene
20. A dopamine-responsive domain in the N-terminal sequence of Pit-1. Transcriptional inhibition in endocrine cell types
21. Adenovirus-mediated herpes simplex virus type-1 thymidine kinase gene therapy suppresses oestrogen-induced pituitary prolactinomas
22. Transcriptional targeting to anterior pituitary lactotrophic cells using recombinant adenovirus vectors in vitro and in vivo in normal and estrogen/sulpiride-induced hyperplasic anterior pituitaries
23. Expression of transgenes in normal and neoplastic anterior pituitary cells using recombinant adenoviruses: Long term expression, cell cycle dependency, and effects on hormone secretion
24. Long-term transgene expression within the anterior pituitary gland in situ: Impact on circulating hormone levels, cellular and antibody-mediated immune responses
25. Tight control of gene expression in mammalian cells by tetracycline-responsive promoters
26. Switching on and off transgene expression within lactotrophic cells in the anterior pituitary gland in vivo
27. Cell-type-specific and regulatable transgenesis in the adult brain: Adenovirus-encoded combined transcriptional targeting and inducible transgene expression
28. Effects of estrogen-induced hyperprolactinemia on endocrine and sexual functions in adult male rats
29. Antiproliferative role of dopamine: Loss of D2 receptors causes hormonal dysfunction and pituitary hyperplasia
30. Pituitary lactotroph hyperplasia and chronic hyperprolactinemia in dopamine D2 receptor-deficient mice
31. Pituitary hyperplasia induced by ectopic expression of nerve growth factor
32. Targeting of transforming growth factor-α expression to pituitary lactotrophs in transgenic mice results in selective lactotroph proliferation and adenomas
33. Characterization of estrogen-induced adenohypophyseal tumors in the Fischer 344 rat
34. A single domain of the estrogen receptor confers deoxyribonucleic acid binding and transcriptional activation of the rat prolactin gene
35. Both Pit-1 and the estrogen receptor are required for estrogen responsiveness of the rat prolactin gene
36. Potent antidopaminergic activity of estradiol at the pituitary level on prolactin release
37. Early involvement of estrogen-induced pituitary tumor transforming gene and fibroblast growth factor expression in prolactinoma pathogenesis
38. In vivo effect of cabergoline, a dopamine agonist, on estrogen-induced rat pituitary tumors
39. Inhibitory effect of cabergoline on the development of estrogen-induced prolactin-secreting adenomas of the pituitary
40. Transfection of human lactotroph adenoma cells with an adenovirus vector expressing tyrosine hydroxylase decreases prolactin release
41. Generation of conditional mutants in higher eukaryotes by switching between the expression of two genes
42. Chronic brain inflammation and persistent herpes simplex virus 1 thymidine kinase expression in survivors of syngeneic glioma treated by adenovirus-mediated gene therapy: Implications for clinical trials
43. Toxicity associated with repeated administration of first-generation adenovirus vectors does not occur with a helper-dependent vector
44. Peripheral infection with adenovirus causes unexpected long-term brain inflammation in animals injected intracranially with first-generation, long-term neurological gene therapy for chronic diseases
45. Expression and dexamethasone regulation of the human corticotropin-releasing hormone gene in a mouse anterior pituitary cell line
46. The use of adenovirus vectors to transfer genes to identified brain cells in vitro
47. Gene transfer into neural cells in vitro using adenoviral vectors
48. Supernatant rescue assay vs. polymerase chain reaction for detection of wild type adenovirus-contaminating recombinant adenovirus stocks
49. Lipopolysaccharide is a frequent contaminant of plasmid DNA preparations and can be toxic to primary human cells in the presence of adenovirus
50. Prolactin release, oestrogens and proliferation of prolactin-secreting cells in the anterior pituitary gland of adult male rats
51. The pharmocokinetics of intravenous and oral sulpiride in healthy human subjects
52. Cell proliferation and death in the irradiated pituitary gland and its modification by growth stimulants
53. Cell type specific and inducible transient transgenesis in the anterior pituitary
54. Clinical evaluation of a two-site immunoradiometric assay for adrenocorticotrophin in unextracted human plasma using monoclonal antibodies